MedTrace Logo

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

NCT00333814 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2011-04-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.

Conditions

  • Intermediate Uveitis
  • Posterior Uveitis

Interventions

DRUG

Dexamethasone

Dexamethasone 350 µg; injection drug delivery system at Day 0

DRUG

dexamethasone

Dexamethasone 700 µg injection drug delivery system at Day 0

DRUG

Sham injection

Sham injection at Day 0

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31
Completion
2009-04-30

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Canada
  • Czechia
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Poland
  • Portugal
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333814 on ClinicalTrials.gov